Cargando…
Iron Administration, Infection, and Anemia Management in CKD: Untangling the Effects of Intravenous Iron Therapy on Immunity and Infection Risk
Patients with chronic kidney disease (CKD) are at increased risk for infection, attributable to immune dysfunction, increased exposure to infectious agents, loss of cutaneous barriers, comorbid conditions, and treatment-related factors (eg, hemodialysis and immunosuppressant therapy). Because iron p...
Autores principales: | Ganz, Tomas, Aronoff, George R., Gaillard, Carlo A.J.M., Goodnough, Lawrence T., Macdougall, Iain C., Mayer, Gert, Porto, Graça, Winkelmayer, Wolfgang C., Wish, Jay B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7380433/ https://www.ncbi.nlm.nih.gov/pubmed/32734254 http://dx.doi.org/10.1016/j.xkme.2020.01.006 |
Ejemplares similares
-
Iron Deficiency in CKD Without Concomitant Anemia
por: Wish, Jay B., et al.
Publicado: (2021) -
Intravenous Iron Therapy in Patients with Iron Deficiency Anemia: Dosing Considerations
por: Koch, Todd A., et al.
Publicado: (2015) -
FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia
por: Macdougall, Iain C., et al.
Publicado: (2014) -
Safety of intravenous ferric carboxymaltose versus oral iron in patients with nondialysis-dependent CKD: an analysis of the 1-year FIND-CKD trial
por: Roger, Simon D., et al.
Publicado: (2017) -
The FIND-CKD study—a randomized controlled trial of intravenous iron versus oral iron in non-dialysis chronic kidney disease patients: background and rationale
por: Macdougall, Iain C., et al.
Publicado: (2014)